-
Loading metrics
A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab
-
Martin Demarchi ,
Roles Writing – original draft
* E-mail: mdemarchi@strasbourg.unicancer.fr
Affiliation Paul Strauss Center, Strasbourg, France
⨯ - Pierre Coliat,
- Philippe Barthelemy,
- Roland Schott,
- Meher BenAbdelghani,
- Michael Kim,
- Jocelyn Chung Shii Hii,
- Peggy Feyaerts,
- Felicia Rui Xia Ang,
- Marie Paule Derde,
- Filip Deforce,
- Thierry Petit,
- Chris Schwabe,
- Chris Wynne,
- Lisa Soyeon Park,
- [ ... ],
- Xavier Pivot
- [ view all ]
- [ view less ]
https://orcid.org/0000-0003-1894-3560
A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab
- Martin Demarchi,
- Pierre Coliat,
- Philippe Barthelemy,
- Roland Schott,
- Meher BenAbdelghani,
- Michael Kim,
- Jocelyn Chung Shii Hii,
- Peggy Feyaerts,
- Felicia Rui Xia Ang,
- Marie Paule Derde
x
- Published: September 23, 2021
- https://doi.org/10.1371/journal.pone.0248222